Analysts Offer Predictions for APLS FY2026 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings of ($0.80) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $44.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same quarter in the prior year, the firm posted ($0.54) EPS. The firm's revenue for the quarter was down 3.2% on a year-over-year basis.

Other analysts have also recently issued reports about the stock. Royal Bank of Canada decreased their price objective on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research note on Thursday, May 8th. The Goldman Sachs Group reduced their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Robert W. Baird dropped their price target on Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Needham & Company LLC cut their price objective on Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Nine equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $40.05.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock traded down $0.43 during mid-day trading on Tuesday, reaching $18.83. 1,172,054 shares of the stock were exchanged, compared to its average volume of 2,335,828. Apellis Pharmaceuticals has a fifty-two week low of $16.10 and a fifty-two week high of $43.15. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -9.28 and a beta of 0.68. The firm has a 50-day simple moving average of $18.31 and a 200 day simple moving average of $25.26. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC grew its stake in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after purchasing an additional 758 shares during the period. Assetmark Inc. boosted its holdings in Apellis Pharmaceuticals by 3,938.7% during the first quarter. Assetmark Inc. now owns 1,252 shares of the company's stock worth $27,000 after buying an additional 1,221 shares during the last quarter. Signaturefd LLC grew its position in shares of Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after buying an additional 918 shares during the period. GF Fund Management CO. LTD. increased its stake in shares of Apellis Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock valued at $70,000 after acquiring an additional 573 shares during the last quarter. Finally, US Bancorp DE raised its position in shares of Apellis Pharmaceuticals by 70.0% in the 4th quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after acquiring an additional 1,327 shares during the period. Institutional investors and hedge funds own 96.29% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).